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Analysis of Apoptosis Protein Expression in Early-Stage Colorectal
Cancer Suggests Opportunities for New Prognostic Biomarkers
Maryla Krajewska,1Hoguen Kim,3 Chul Kim,4 Haeyoun Kang,5 KateWelsh,1Shu-ichi Matsuzawa,1
Michelle Tsukamoto,1Ronald G.Thomas,2 Nuria Assa-Munt,1Zhe Piao,1Koichi Suzuki,1
Manuel Perucho,1Stan Krajewski,1andJohn C. Reed1
Abstract Purpose:Although most stage II colon cancers are potentially curable by surgery alone,f20%
of patients relapse, suggesting a need for establishing prognostic markers that can identify
patients whomay benefit from adjuvant chemotherapy.We tested the hypothesis that differences
in expression of apoptosis-regulating proteins account for differences in clinical outcome among
patients with early-stage colorectal cancer.
Experimental Design:Tissue microarray technology was employed to assay the expression of
apoptosis-regulatingproteinsby immunohistochemistry in106 archival stage IIcolorectal cancers,
making correlationswith disease-specific survival.The influenceofmicrosatellite instability (MSI),
tumor location (left versus right side), patient age, and gender was also examined.
Results: Elevated expression of several apoptosis regulators significantly correlated with either
shorter (cIAP2; TUCAN) or longer (Apaf1; Bcl-2) overall survival in univariate and multivariate
analyses. These biomarkers retained prognostic significance when adjusting for MSI, tumor
location, patient age, and gender. Moreover, certain combinations of apoptosis biomarkers were
highly predictive of death risk from cancer. For example, 97% of patients with favorable tumor
phenotype of cIAP2low plus TUCANlow were alive at 5 years compared with 60% of other
patients (P = 0.00003). In contrast, only 37% of patients with adverse biomarkers (Apaf1low
plusTUCANhigh) survived compared with 83% of others at 5 years after diagnosis (P< 0.0001).
Conclusions: Immunohistochemical assays directed at detection of certain combinations of
apoptosis proteins may provide prognostic information for patients with early-stage colorectal
cancer, and therefore could help to identify patients who might benefit from adjuvant chemo-
therapy or who should be spared it.
Colorectal cancer is the second leading cause of cancer-related
death in the United States and most industrialized countries and
the fourth leading cause of cancer-related death worldwide (1).
Currently, selecting patients for postoperative adjuvant chemo-
therapy relies mainly on pathologic and clinical staging but
inadequately addresses the heterogeneity in survival among
similarly staged patients. Although stage II (Dukes’ B) colon
cancer is potentially curable by surgery alone,f20% of patients
relapse (reviewed in refs. 2, 3). Clinical guidelines for
management of patients with no histologic evidence of lymph
node invasion are controversial (4, 5), primarily because it is
not currently possible to discriminate which patients have
micrometastatic disease at the time of diagnosis. A need
therefore exists for establishing prognostic markers that can
identify patients who may benefit from adjuvant chemotherapy.
Adenocarcinoma of the colon results from a multistep
process involving changes in the expression and function of
genes relevant to cell division, cell migration, and programmed
cell death (apoptosis; reviewed in ref. 6). In normal colonic
mucosa, a self-renewing population of stem cells located in the
crypt region of the colonic villi gives rise to progeny which
differentiate into surface epithelial cells, and migrate to the
villus tip where they eventually die by programmed cell death
and are discarded into the lumen of the bowel. Defects in
intrinsic cell suicide mechanism thus can contribute to cell
accumulation in the colon, promoting malignancy. Apoptosis
also figures prominently in the cytotoxic action of chemother-
apeutic drugs and ionizing radiation thus making defects in
apoptosis mechanisms relevant to problems of chemoresistance
and radioresistance. Moreover, defects in apoptosis pathways
can contribute to metastasis, allowing epithelial cells to survive
in a suspended state, thereby promoting their hematogenous or
lymphatic dissemination (7).
The human genome contains >120 genes directly involved in
apoptosis regulation, representing core components of or direct
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inputs into the cell death machinery (http://www.apoptosis-
db.org; ref. 8). We tested the hypothesis that differences in the
expression of specific apoptosis-regulating proteins could
account for differences in clinical outcome among patients
with early-stage epithelial malignancies, focusing on colorectal
cancer as a test case. Accordingly, monospecific antisera were
generated against several apoptosis proteins and applied for
immunohistochemical analysis of archival tumor specimens.
Tissue microarray technology was used to increase the
throughput of this analysis, permitting rapid testing of multiple
antibodies on replicate sections of arrays of archival colorectal
cancer specimens derived from patients with stage II disease
treated by surgery with curative intent. The findings reveal
examples of altered regulation of apoptosis protein expression
in stage II colorectal cancer and suggest that simple immuno-
histochemical assays directed at detection of certain combina-
tions of apoptosis proteins could have potential utility as
prognostic biomarkers for patients with early-stage cancer. If
confirmed in additional cohorts, selected apoptosis biomarkers
identified here may help to distinguish early-stage patients who
may benefit from adjuvant chemotherapy.
Materials andMethods
Patient specimens. Colorectal cancer specimens were obtained from
the Department of Pathology, Yonsei University, Seoul, Korea, under
the Institutional Review Board approval. Tissue samples included 106
primary tumors derived from patients with stage II colorectal cancer (as
defined by American Joint Committee on Cancer and Union
Internationale Contre le Cancer criteria) who had undergone curative
surgical resection between 1986 and 1996 and for whom follow-up
information was available. Cases without postoperative adjuvant
chemotherapy were collected, whereby 63 patients survived without
recurrence, seven patients had recurrent disease, and 36 patients died
from colorectal cancer. Thus, while not an unbiased sequential case
series, the survival profile of this cohort closely resembles that of a
random population of stage II colorectal cancer patients, with 72.5% of
individuals alive at 5 years (data not shown). Clinical data represent a
median follow up of 66 months. The following demographic
characterized the investigated cohort: females (40 of 106, 40%), males
(66 of 106, 62%); younger patients (dichotomized at median age,
55 years; 59 of 106, 56%), older population (47 of 106, 44%). Fresh
snap-frozen samples obtained by cryofractionation methods were used
for analysis of microsatellite instability (MSI), whereas formalin-fixed
paraffin-embedded samples were used for tissue microarray and
immunohistochemical analysis. Patient data were collected retrospec-
tively from hospital records and the Korean National Statistics Office.
Patients with double primary malignancy in other organs and a case of
familial adenomatous polyposis coli were excluded from the analysis.
Only patients whose primary cause of death was due to colorectal
cancer were eligible for inclusion. Individuals whose tumors had
positive circumferential margins were not included in the study. We
defined right-sided tumors as those originating proximal to the splenic
flexure and left-sided as those arising distal to this site.
Antibodies. Polyclonal antisera for Survivin (AR-26), Apaf1 (AR-25),
XIAP (AR-27A), and SMAC (AR-50B) were generated in New
Zealand rabbits using recombinant protein immunogens. Survivin
and SMAC (full-length proteins) and Apaf1 (residues 1–420) were
produced as glutathione S-transferase fusion proteins and affinity-
purified as described previously (9). Affinity-purified His6-tagged-
XIAP (BIR2) recombinant protein was produced as described
previously (10) and was used as an immunogen for producing
XIAP-specific antiserum. An additional anti-Apaf1 antibody was
generated in rabbits using a synthetic peptide (NH2-CGPKYVVP-
VESSLGKEKGLE-amide) corresponding to residues 264 to 282 of
human (hu) Apaf1, which was synthesized with an NH2-terminal
cysteine appended to permit conjugation to maleimide-activated
carrier proteins KLH and OVA (Pierce, Rockford, IL, Inc.; ref. 11) and
used to generate a rabbit polyclonal antiserum (AR-23). An anti-AIF
serum was produced in rabbits using a synthetic peptide
corresponding to residues 151 to 170 of human AIF. The generation
of Bcl-2, Bcl-XL, Bax, Bid, and TUCAN-specific antisera has been
described elsewhere (12–14). Anti-cIAP1 and cIAP2 antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and
R&D Systems, Inc. (Minneapolis, MN), respectively; h-Catenin
antiserum from BD Transduction Laboratories (Lexington, KY); and
antibodies to p53 (clone DO-7), MIB-1, and BAG1 (clone KS-6C8)
from DAKO (Carpinteria, CA). The monospecificity of all antibodies
for their intended protein targets was confirmed by SDS-PAGE/
immunoblot analysis. Only those antibodies showing selective
immunoreactivity with target antigens were employed for subsequent
immunohistochemical assays.
Tissue microarrays. To construct colorectal cancer microarrays, two to
four cylinders of 1-mm-diameter tissue were cored from representative
areas of formalin-fixed tumors embedded in paraffin blocks and arrayed
into a new recipient paraffin block with a custom-built precision
instrument (Beecher Instruments, Silver Spring, MD). Serial sections
(4 Am) were applied to APES-coated slides (Sigma, St. Louis, MO).
Immunohistochemistry. Dewaxed tissue sections were immunos-
tained using a diaminobenzidine-based detection method as de-
scribed in detail, employing the Envision-Plus-Horseradish Peroxidase
(HRP) system (DAKO) and using an automated immunostainer
(DAKO Universal Staining System; ref. 15). Antisera specific for
Survivin, XIAP, Apaf1, TUCAN, AIF, SMAC, Bax, and Bid were
applied at 1:3,000 to 10,000 (v/v), whereas antibodies against Bcl-2
and Bcl-XL at 1:2,000 (v/v). The dilutions of cIAP1, cIAP2, and h-
Catenin antibodies were 1:600 (v/v); BAG1 and MIB-1 were 1:100;
and p53 was at 1:50 (v/v). For all polyclonal antisera employed, the
immunostaining procedure was done in parallel using preimmune
serum to verify specificity of the results. Initial confirmations of
antibody specificity also included experiments in which antiserum
was preabsorbed with 5 to 10 Ag/mL of either synthetic peptide or
recombinant protein immunogens.
The scoring of tumor immunostaining was based on the percentage
of immunopositive cells (0-100) multiplied by staining intensity score
(0/1/2/3), yielding scores of 0 to 300. Results from triplicate or
quadruplicate cores were averaged. A preliminary analysis of the data
for TUCAN (13) and Bid (14) has been published previously.
Microsatellite instability. Specimens were analyzed for MSI by PCR
amplification of microsatellite markers using DNA from either snap-
frozen tumor specimens or from formalin-fixed paraffin blocks. The
laser capture cryostat microdissection method using H&E-stained
cryosections containing >80% of tumor cells was used for sample
collection and extraction of DNA. Extracted DNAs from tumors and
matched normal mucosae were PCR amplified at six microsatellite loci
to evaluate the MSI. The markers included the National Cancer
Institute–recommended panel of five markers, plus BAT40 (16).
The sampling of specimens from paraffin blocks was done on the
106 paraffin blocks using Beecher Inst. Arrayer. One millimeter in
diameter tumor regions were cored from the paraffin blocks and the
cylinders were cut in smaller pieces for the DNA isolation described
above. The tumors were analyzed for MSI by PCR amplification of
BAT26 (17). Analysis exclusively of tumor was adequate for MSI
determination as the shorter BAT26 allele associated to Africans is
absent in the Korean population (not found in over 500 individuals
analyzed). PCR products were separated in 6% polyacrylamide gels
containing 5.6 mol/L urea followed by autoradiography. MSI was
determined by the mobility shift of the PCR products. In tumors with
MSI, additional bands were found relative to the normal alleles. MSI in
three or more markers of which more than two mononucleotide repeat
markers were included was classified as MSI-H whereas all others were
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classified as microsatellite stable. Only 1 of the 39 cases classified as
MSI-H because of positivity for BAT25 and D2S123 was negative for the
commonly used marker, BAT26.
Immunoblotting. Colon cancer specimens (n = 10) with high
ratios of cancer cells relative to stroma (>70%) were selected for
immunoblotting analysis. The protein lysates were prepared without
additional microdissection or fractionation. The tumor lysates and
the samples of the normal mucosa from the same patients were
prepared using modified radioimmunoprecipitation assay buffer
[50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 0.25% Na-deoxycholate,
1% NP40, 1 mmol/L EDTA, 1 mmol/L Na3VO4, 1 mmol/L NaF,
1 mmol/L phenylmethylsulfonyl fluoride] containing complete
protease inhibitor cocktail (Sigma), Pan-Caspase inhibitors z-Asp-
2,6-dichlorobenzoyloxymethylketone (Bachem, Torrance, CA), and
zVAD-fmk (Calbiochem, La Jolla, CA). Samples were normalized for
total protein content (100 Ag), resolved by SDS-PAGE (12-15% gels),
and proteins were transferred to polyvinylidene difluoride membranes
(Amersham Pharmacia, Piscataway, NJ). After blocking with 5% skim
milk in TBST [50 mmol/L Tris (pH 7.6), 150 mmol/L NaCl, 0.05%
Tween 20] for 2 hours, blots were incubated overnight with specific
antisera at 1:1,000 to 1:10,000 (v/v) dilutions at 4jC. After incubation
with HRPase-conjugated secondary goat anti-rabbit (either Bio-Rad,
Hercules, CA or Santa Cruz Biotechnology) antibody at room
temperature for 1 hour, immunodetection was accomplished by an
enhanced chemoluminescence method (Amersham), with exposure to
X-ray film (Kodak/XAR). Densitometry was done to quantify the
intensity of bands, using Image-pro Plus software.
Statistical analysis. Data were analyzed using the STATISTICA
software package (StatSoft, Tulsa, OK). Overall survival (OS), defined
as the time from study entry to death, was determined in univariate
survival analysis using the Kaplan-Meier method. Log-rank test was
used for correlation of immunostaining data with the patient
survival. Multivariate Cox proportional hazards models were fitted
to the data to assess which biomarkers were independently associated
with OS. All factors that had prognostic significance when considered
alone (P V 0.05) were entered into a multiple regression analysis
whereby hazard ratios (HR) and significance levels were estimated. In
backward selection, a factor that was not statistically significant was
removed from the model until all remaining factors were significant.
The 95% confidence interval (95% CI) for HR was calculated by a
formula exp[b F 1.960SE(b)].
Results
Immunohistochemical analysis of apoptosis biomarkers in
normal colonic mucosa and colorectal cancer. A tissue micro-
array was constructed using primary tumor specimens derived
from a cohort of 106 patients presenting with stage II disease
to a single institution, who were treated by surgical resection
with curative intent. Microarrays were immunostained using
antibodies specific for IAP family proteins (Survivin, XIAP,
cIAP1, and cIAP2), Bcl-2 family proteins (Bcl-2, Bcl-XL, Bax,
and Bid), mitochondrial proteins (SMAC and AIF), and other
apoptosis regulators such as Apaf1, TUCAN, and BAG1. In
addition, because previous studies showed prognostic signif-
icance in colon cancer (18–20), immunostaining was done
for h-Catenin, p53, and the cell proliferation marker MIB-1.
All immunostaining results were quantified according the
percentage of immunopositive tumor cells (0-100%) and
immunointensity (on a 0-3 scale with reference to internal
control cells), and then an immunoscore was calculated from
the product of the percentage immunopositivity and immu-
nointensity (0-300). Several of the 106 tumor specimens on
the array (f65%) contained adjacent normal colonic mucosa
(59-70), depending on the particular slide, permitting side-by-
side comparisons of immunostaining results for normal versus
malignant epithelium. In addition, four specimens of normal
colon derived from individuals who were not diagnosed with
colon cancer were stained separately.
Immunohistochemical analysis of tumor tissues on the
microarray revealed several examples of cancer-specific alter-
ations in the expression of apoptosis-regulatory proteins.
Figure 1 shows some examples of the immunostaining results
and Fig. 2 summarizes the data. The mean intensity of
immunostaining was significantly higher in the invasive cancer
compared with normal colonic epithelium for all investigated
proteins (Fig. 1C, E-F, KM, O, P) with the exception of Bcl-2, Bax,
and AIF (Fig. 1G and H). Moreover, whereas immunostaining
results varied widely among specimens examined, the immu-
noscores for a portion of the cancer specimens clustered into
groups displaying clear elevations in immunoreactivity when
compared with normal specimens, including cIAP1, cIAP2,
XIAP, Survivin, Bcl-XL, BAG1, p53, and MIB-1 (Fig. 2).
Immunoblot analysis of apoptosis regulators in colon carcinoma.
To corroborate the immunohistochemical data, five frozen
colon cancer specimens from the same cohort were identified
that had sufficient amounts of both adjacent normal (N) and
tumor (T) tissue for immunoblot analysis using antibodies
specific for IAPs, Apaf1, and other proteins. Detergent lysates
of these tissue specimens were prepared and normalized for
total protein content before SDS-PAGE/immunoblot analysis
(Fig. 3A). Densitometry analysis was also done to quantify
band intensities, and the results from the loading control blot
were used to normalize all data (Fig. 3B). Higher levels of
cIAP2, XIAP, Survivin, and Apaf1 were detected in every
specimen evaluated compared with case-matched normal
tissue. Levels of cIAP1 protein, as well as the antiapoptotic
protein TUCAN, were elevated in some tumor specimens
compared with normal but not others. These (Fig. 3A) and
other (Fig. 3C) immunoblot data also confirmed the specificity
of the antibody reagents. Although done on small number of
samples, the data presented here and elsewhere (21) confirmed
monospecifity of the applied antibodies and corroborated the
immunohistochemical differences seen in normal and malig-
nant colon.
Relation of apoptosis biomarkers to microsatellite instability,
tumor location, and other patient information. In several prior
studies of early-stage colon cancer, MSI negativity, male sex,
left-sided tumors, and older patient age were associated with
unfavorable outcome or inadequate response to adjuvant
chemotherapy (22–24). Therefore, in the investigated cohort,
we compared the expression of apoptosis biomarkers with these
tumor and patient characteristics to preliminarily explore, if
differences in expression of these proteins might be related to
the known differences in the clinical behavior of colon cancers.
Comparison of MSI (n = 22, 21%) versus microsatellite stable
(n = 83, 79%) tumors revealed statistically significant differences
in the immunopercentage data for cIAP1, cIAP2, TUCAN, and
p53 staining (Fig. 4A) but not Apaf1, XIAP, Survivin, AIF, SMAC,
Bcl-2, Bax, Bcl-XL, Bid, BAG1, h-Catenin, or MIB-1, using an
unpaired t test and a threshold of P V 0.05 without correction for
multiple comparisons. Significant differences in immunoscore
data were also observed for cIAP1, cIAP2, XIAP, TUCAN, Bax,
and h-Catenin (Fig. 4B), using a P V 0.05 as a cutoff for unpaired
t tests, again without correction for multiple comparisons.
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A similar comparison was done for left-sided (n = 76, 72%)
versus right-sided (n = 30, 28%) tumors, because tumors arising
in these different anatomic locations are thought to arise via
different mechanisms (23). In the investigated cohort, immu-
nopercentage data were significantly higher in left-sided
compared with right-sided tumors for TUCAN and p53
(Fig. 4A), the latter observation consistent with prior reports
(25). Immunoscore data were significantly higher for Bcl-XL in
left-sided compared with right-sided tumors, whereas Apaf1 was
significantly lower in left-sided compared with right-sided
tumors (Fig. 4B).
Correlations of apoptosis biomarkers with patient survival. To
correlate apoptosis biomarkers with patient survival, we
empirically dichotomized immunostaining at the median,
comparing the survival of patients whose tumor immuno-
scores were above the median with those below the median.
A traditional method for dichotomizing p53 data was used,
where immunopercentage of >20 % is considered positive
(26), but similar results were obtained by using values
between 5% and 25% (data not shown). Note that increases
in p53 immunostaining can be due to several causes,
including mutations that stabilize the p53 protein, loss of
Mdm2 expression, alterations in p53 phosphorylation, and
other events (reviewed in ref. 27). For univariate survival
analysis, the Kaplan-Meier method was applied, and the
differences between survival curves were assessed by the log-
rank test.
In the investigated cohort, significant correlations were
observed between shorter OS and immunoscores indicative
of higher TUCAN expression (P < 0.0001), higher cIAP2 (P =
0.003), lower Apaf1 (P = 0.0003), lower Bcl-2 (P = 0.001),
and lower SMAC (P = 0.04; Fig. 5A). Univariate analysis also
showed significant correlations of shorter OS with immuno-
percentage data indicative of higher TUCAN (P < 0.0001),
higher cIAP2 (P = 0.0002), higher p53 (P = 0.03), lower
Apaf1 (P = 0.01), and lower Bcl-2 (P = 0.0004) immuno-
positivity (Fig. 5B). In contrast, significant correlations with
survival were not found for biomarkers cIAP1, XIAP,
Survivin, AIF, Bcl-X L, Bax, Bid, BAG1, h-Catenin, or MIB-1
(data not shown).
Fig. 1. Examples of immunohistochemical
analysis of apoptosis proteins expression
in normal and malignant colon.Tissue
microarray blocks were prepared using
1-mm-diameter punches from106
colorectal carcinoma specimens.Tissue
sections were immunostained using various
antisera followed by detection using a
HRPase-basedmethod with
diaminobenzidine calorimetric substrate
(brown). Nuclei were counterstained with
hematoxylin (blue). Representative data:
A, colorectal cancer microarray slide stained
for cIAP2. Magnification,5. Examples
of immunostaining of normal colonic
epithelium are presented for cIAP1
(B,100), Survivin (D,150), SMAC
(E ,150), AIF (G,150), andTUCAN
(K ,20). Immunostaining results in regions
of invasive cancer are shown for SMAC
(F ;400), AIF (H,250), Apaf1
(I-J,200),TUCAN (L ,20;M,400),
and Bcl-2 (N,150). Examples ofmalignant
and the adjacent normal colonic epithelium
are presented for cIAP2 (C,40),
p53 (O,150), andMIB-1 (P,400).The
specificity of these immunostaining results
was confirmed by control stainings done
using either preimmune serum or immune
antisera, whichhad been preabsorbed with
the relevant immunogens (data not shown).
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Fig. 2. Comparison of immunoscores for normal and malignant colon tissue. Immunoscores (y-axis) for normal and malignant colon epithelium are summarized as dot
histograms.
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Furthermore, MSI positivity, right-sided tumor location,
and younger age were associated with significantly better
overall survival (Fig. 5C), consistent with prior reports
(28, 29).
Calculation of HRs (with 95% CI) showed a relative risk of
death due to colorectal cancer for patients with immunoscore
(apoptosis markers) or immunopercentage (p53) data above the
median (‘‘high’’) in this cohort as follows: TUCAN (HR, 6.57;
95% CI, 2.71-15.96), cIAP2 (HR, 3.19; 95% CI, 1.48-6.85), p53
(HR, 2.28; 95% CI, 1.09-4.77), Apaf1 (HR, 0.26; 95% CI, 0.12-
0.56), Bcl-2 (HR, 0.28; 95% CI, 0.14-0.58), and SMAC (HR,
0.46; 95% CI, 0.22-0.97; Table 1). Thus, of the 16 biomarkers
evaluated, six showed correlations with patient survival in this
cohort of stage II colorectal cancer patients treated with surgery
alone.
Similar correlations with survival were obtained for TUCAN,
cIAP2, Apaf1, and Bcl-2 when MSI-positive tumors were
excluded from the analysis (data not shown) thus excluding
bias that might arise from representation of tumors that arise
through an alternative pathway compared with most colon
cancers. Similarly, when the analysis was limited to left-sided
tumors, TUCAN, cIAP2, Apaf1, and Bcl-2 remained significantly
associated with OS (data not shown).
Multivariate analysis of apoptosis biomarker association with
patient survival. A Cox proportional hazards model was used
to evaluate whether apoptosis biomarkers showed independent
prognostic significance when MSI status, tumor location,
gender, and patient age were included as variables (Table 1).
In multivariate analysis, TUCAN, cIAP2, Apaf1, and Bcl-2
maintained independent prognostic significance (P < 0.0001,
Fig. 3. Analysis of apoptosis protein
expression in colon carcinoma by
immunoblotting. A , lysates from five
matched pairs of colon carcinoma (T) and
normal colonic mucosa (N) specimens
were normalized for total protein content
(100 Ag per lane) and subjected to
SDS-PAGE/immunoblot analysis, using the
antisera specific for c-IAP1, c-IAP2,
XIAP, Survivin, Apaf-1, andTUCAN. B,
immunoblot data were quantified by
scanning-densitometry using Pro-Image
software. Data are expressed as arbitrary
densitometric units. Datawas transformed
to percentages of the densitometric levels
observed on scans from loading control.
A nonspecific band obtained during
preblocking procedure with a secondary
ECL antibody (Bio-Rad), servedas a loading
control. C, an example is provided of the
analysis done to verify specificity of
antibodies. Incubation with SMAC
antiserum detected only SMAC in vitro ^
translated protein. Detergent lysates were
prepared from various human tissues,
normalized for total protein content
(50 Ag), and subjected to SDS-PAGE/
immunoblot assay using antiserum specific
for SMAC. Molecular weight markers are
indicated inkilodaltons. Antiserawere raised
against recombinant proteins and synthetic
peptides for immunodetection of various
apoptosis-relevant proteins.
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P = 0.009, P = 0.003, and P = 0.0009, respectively) in the
investigated cohort. HR calculations indicated a relative risk of
death from colorectal cancer at 7.7 times higher for high
TUCAN tumors and 2.9 times higher for high cIAP2 compared
with a reduced hazard rate of f75% for high Apaf1 and high
Bcl-2 tumors (Table 1).
Combinations of biomarkers. Because certain apoptosis
proteins showed significant prognostic value, we asked whether
combining pairs of biomarkers more accurately identified
subgroups of patients with distinct survival characteristics
compared with use of only a single biomarker.
Accordingly, we compared patients with two favorable
variables (e.g., low cIAP2 and high Apaf1) versus all other
patients in this cohort. Of the 94 patient samples successfully
analyzed for cIAP2 and Apaf1, 25 (27%) had both low cIAP2
and high Apaf1 immunoscores. All (100%) of these patients
were alive at 5 years after diagnosis compared with only 60%
alive among the other patients (P = 0.00001; Fig. 5D).
Combining the two favorable variables of low cIAP2 and low
TUCAN produced similar results. Among patients with a
combination of low cIAP2 and low TUCAN, 97% were alive,
compared with only 60% alive among the other patients (P =
0.00003; Fig. 5D). Likewise, 3% of the patients whose tumors
expressed a combination of TUCANlow and Bcl-2high (two
favorable biomarkers) died of colorectal cancer compared with
45% of the others. However, when patients with two adverse
biomarkers (low Apaf1 and high TUCAN) were compared with
other patients, only 37% of patients with this combination of
proteins remained alive compared with 83% of others at 5 years
after diagnosis (P < 0.0001; Fig. 5D). The discrepancy was even
larger at 8 years of follow-up, with 0% versus 82% overall
survival for the Apaf1low plus TUCANhigh group compared with
other patients. Examination of combination data for another
pair of adverse biomarkers (cIAP2high plus Bcl-2low) revealed
that 17% of the patients were alive in this group 5 years after
surgery compared with 76% of others (P = 0.002; Fig. 5D).
Thus, pairwise combinations of certain apoptosis biomarkers
identified groups of patients at extremely high or low risk of
relapse within this cohort of patients with early-stage colorectal
cancer.
Fig. 4. Correlations of protein immunopercentage (A) and immunoscore (B) with MSI status and anatomic location of colorectal carcinomas. Box andwhisker plots display
the distribution of immunopercentage (A) and immunoscore (B) data for apoptosis-relevant proteins expressed in colorectal tumors.The mean immunopercentage/
immunoscore is plotted as amiddle point.Box ,FSE;whiskers ,FSD. TheANOVA test was used for statistical comparisonof immunostaining data inMSI versusmicrosatellite
stable (MSS) or in left-sided (L) versus right-sided (R) tumors.
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Discussion
Differences in long-term survival of patients with early-stage,
resectable colon cancer are most often ascribed to the presence
or absence of micrometastases that are undetectable at the time
of diagnosis. Defects in apoptosis can contribute to a wide
variety of aggressive tumor phenotypes, including conferring an
ability of tumor cells to survive after detachment from
extracellular matrix and thus facilitating metastasis (reviewed
in ref. 30). Tumor cells with resistance to apoptosis have also
recently been shown to survive (and grow) intravascularly,
when adherent to endothelial cells in distal capillary beds (31).
For these reasons, we examined the expression of apoptosis-
regulatory proteins in early-stage colorectal cancers, making
associations with patient survival.
The purpose of this study was to determine whether
alterations in the expression of apoptosis-regulatory proteins
occur in colorectal cancers and to explore whether changes in
apoptosis gene expression alone or in conjunction with other
biomarkers, such as p53, h-Catenin, and MIB-1, might be
predictive of survival in stage II colorectal cancer patients.
We found tumor-associated alterations in the expression of
multiple apoptosis-relevant proteins in colorectal tumors, based
on comparisons with adjacent morphologically normal colonic
epithelium. One caveat in interpreting such comparisons of
transformed and normal mucosa, however, is that genetic or
epigenetic lesions could be present in adjacent epithelium,
which seems normal in morphology (32). Nevertheless, our
findings suggest that alterations in the expression of several IAP
family proteins (XIAP, cIAP1, and cIAP2) as well as Apaf1 occur
commonly in colon cancers, providing insights into the
pathogenesis of this disease. It should be recognized however
that the activity of many of the proteins evaluated here can be
influenced by posttranslational modifications; thus, the levels of
protein do not necessarily correlate with protein activity.
The mechanisms responsible for these alterations are a matter
for speculation, but recent data suggest some possibilities. For
example, the transcription factor nuclear factor-nB has been
reported to induce expression of cIAP1, cIAP2, and XIAP in some
types of cells (33), suggesting that tumor-associated increases in
nuclear factor-nB activity could play a role in dysregulating
expression of several IAP family genes. Indeed, the gene
encoding cIAP2 contains several consensus binding sites for
nuclear factor-nB in its promoter region, and induction of cIAP2
expression following nuclear factor-nB activation is consistently
observed in multiple cell types. For Apaf1, it has been shown that
retinoblastoma tumor suppressor protein (pRB) and E2F
regulate the expression of this important proapoptotic protein
(34). The Apaf1 gene promoter contains E2F-binding sites and is
a direct transcriptional target of certain E2F family transcription
factors (34). Because E2F family proteins are suppressed by pRB
(reviewed in ref. 35), our finding that Apaf1 protein levels are
elevated (compared with normal colon) in roughly two thirds of
colorectal carcinomas raises the possibility that the pRB pathway
may be functionally inactivated in these tumors thus resulting in
deregulation of E2F and overexpression of Apaf1. However, in
contrast to increased Apaf1 protein levels observed in our study,
loss of heterozygosity of the chromosomal region encompassing
the APAF1 gene at 12q23 has been reported during progression
of colorectal cancer, in association with reduced levels of Apaf1
mRNa (36). Thus, APAF1 expression may be influenced by
multiple mechanisms in colorectal cancers.
p
Fig. 5. Correlations of single and combined apoptotic biomarkers, MSI, age, and tumor locationwith overall survival of colorectal cancer patients. Immunoscore (A) and
immunopercentage (B) data for selected apoptotic proteins were dichotomized into high (red) versus low (blue) expression groups based on the median values; <20%
of p53 positive cells were used as cut-off for analysis of p53 immunostaining. C, based on PCRanalysis, tumor samples were scored as exhibiting high-frequencyMSI or
as microsatellite stable (MSS). Right-sided tumors were defined as those originating proximal to the splenic flexure, and left-sided as those arising distal to this site. Median
age was used to dichotomize patients into older versus younger groups.The Kaplan-Meier methodwas applied to generate the survival curves, and univariate survival
distributions were compared by the log-rank test. Pairwise combinations of apoptosis biomarkers were compared with OS for colorectal cancer patients (D).
Table 1. Univariate and multivariate Cox proportional hazards analysis of patients with stage II colorectal cancer
managed without adjuvant chemotherapy
Cox proportional hazards analyses
Univariate Multivariate
Factor HR (95% CI) P Factor HR (95% CI) P
MSS 3.749 (1.132-12.417) 0.03
Age 3.671 (1.749-7.705) 0.0006
Left side 2.622 (1.013-6.782) 0.05
TUCAN 6.570 (2.706-15.956) 0.00003 TUCAN 7.658 (3.073-19.911) <0.0001
cIAP2 3.188 (1.483-6.853) 0.003 cIAP2 2.908 (1.298-6.516) 0.009
p53 2.278 (1.088-4.768) 0.03
Apaf1 0.255 (0.116-0.560) 0.0007 Apaf1 0.284 (0.125-0.647) 0.003
Bcl-2 0.282 (0.136-0.584) 0.0007 Bcl-2 0.251 (0.111-0.567) 0.0009
SMAC 0.464 (0.222-0.970) 0.04
NOTE: Only those variables showing statistical significance (P V 0.05) are presented. All factors that showed prognostic significance in the univariate Cox analysis were
included in themultivariate Cox proportional hazards model. Only significant results (P V 0.05) are presented.
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In this study, we characterized the expression of apoptosis
biomarkers in cohorts of early-stage colorectal cancer patients
who did not receive standard 5-fluorouracil-based adjuvant
chemotherapy after surgery. The survival benefit of chemother-
apy in stage II disease is debated, ranging from reports claiming
25% to 30% reduction in mortality (37) to other studies
negating significant survival gain (38). Currently, American
Society of Clinical Oncology does not recommend the routine
use of adjuvant chemotherapy for patients with stage II colon
cancer (38). Nevertheless, Surveillance, Epidemiology, and End
Results Medicare data suggest that 27% of stage II patients do
receive adjuvant chemotherapy in the United States (39). It is
difficult to know which early-stage patients benefit from 5-
fluorouracil-based chemotherapy versus which patients may
have been unnecessarily subjected to the toxicity of chemother-
apy. A need therefore exists for practical laboratory tests that can
be applied to early-stage colon cancers for dichotomizing
individuals into low-risk versus high-risk groups, thereby
providing a rational basis to the postoperative management of
these patients. By retrospectively investigating a cohort of patients
who did not receive adjuvant chemotherapy, we sought to gain
insights into the relevance of certain biomarkers to clinical
outcome, focusing on apoptosis as a pathway for interrogation.
Although only an exploratory study, we found that altered
expression of cIAP2, TUCAN, Apaf1, and Bcl-2 exhibited the
strongest correlations with OS in this cohort of patients. In
univariate and multivariate analyses, patients with tumors
displaying low levels of cIAP2 or TUCAN and high levels of
Apaf1 or Bcl-2 enjoyed longer OS compared with those with
cIAP2high, TUCANhigh, Apaf1low, or Bcl-2low tumor phenotype.
The survival of these patients with favorable apoptosis
biomarker profiles seems to have been similar regardless of
their MSI status, tumor location, age, or gender.
Furthermore, analysis of a variety of pairwise combinations
of apoptosis biomarkers suggested that combining a relatively
small number of variables might be adequate to achieve
strong prognostic power. For example, f28% of the tumors
analyzed had both high TUCAN and low Apaf1, two adverse
biomarkers. Among patients whose tumors expressed TUCANhigh
and Apaf1low, only 37% of patients remained alive compared
with only 83% of others at 5 years after surgery. Thus, the
combination of TUCANhigh and Apaf1low may identify a
subset of early-stage colorectal cancer patients at particularly
high risk of relapse and thus proposed for adjuvant
chemotherapy. Similarly, the combination of high Apaf1
and low cIAP2, two favorable biomarkers, revealed that none
of the patients with this tumor characteristic relapsed after
surgery (with 5-year median follow36-up) compared with
60% of others. Likewise, 3% of the patients whose tumors
expressed a combination of low TUCAN and high Bcl-2 (two
favorable biomarker results) died of colon cancer compared
with 45% of the others. Thus, patients whose tumors display
either an Apaf1high plus cIAPlow or a TUCANlow plus Bcl-2high
phenotype may not benefit from adjuvant chemotherapy.
It is interesting to put these results obtained for apoptosis
biomarkers into the context of previous investigations of these
and other biomarkers in early-stage colorectal cancer. For
example, among IAP family proteins, higher levels of Survivin
immunostaining were previously correlated with shorter
survival in a study of patients with Dukes’ stage B patients
who did not undergo preoperative or postoperative chemo-
therapy (40). In contrast, we failed to observe a significant
correlation of Survivin with patient outcome but used
different methods for dichotomizing data. Several prior
studies have examined the prognostic significance of Bcl-2,
finding an association of this biomarker with favorable
outcome (41–43). Association of this antiapoptotic protein
with longer OS may be a reflection either of the ability of Bcl-
2 to be converted from a protector to a killer through
interactions with other proteins (44), or related to the
unexplained role of Bcl-2 in suppressing cell cycle entry
(45, 46). Of the other Bcl-2 family members assessed here
(e.g., Bcl-XL, Bax, and Bid), only Bax has been examined
previously in stage II patients, where expression of this
protein was found to be associated with higher risk of local
relapse. The role of tumor suppressor p53 as an indicator of
aggressive disease is well documented (reviewed in ref. 47),
and our data support a role for immunohistochemical
evaluation of p53 as a promising prognostic marker in
early-stage colorectal cancer among patients who did not
receive chemotherapy (48).
The other biomarkers evaluated here, SMAC and AIF, have
not heretofore been studied in colorectal cancer patients.
Approximately one sixth of unselected colon tumors
accumulate hundreds of thousands of somatic mutations in
microsatellite sequences (49). MSI-positive tumors display a
mutator phenotype characterized by an over-two-orders-of-
magnitude higher mutation rate than normal cells (49, 50).
Within our study population, patients with MSI-positive
tumors had a significant survival advantage over individuals
with MSI-stable cancers, thus confirming results reported by
others (reviewed in ref. 51). The molecular basis for these
differences in outcome for MSI-positive tumors is only partly
understood. Interestingly, MSI positivity was associated in the
investigated cohort with significantly lower expression of
antiapoptotic proteins cIAP1, cIAP2, and TUCAN, and with
lower expression of proapoptotic protein Bax. It remains to be
determined whether differences in expression of these apo-
ptosis proteins contribute to the superior survival of patients
with MSI-positive tumors.
These findings based on retrospective analysis of non-
randomized archival tumor material from a single Asian
institution suggest that further studies are warranted to
determine whether apoptosis biomarkers can discriminate
populations of early-stage colorectal cancer patients benefiting
from versus not requiring adjuvant chemotherapy in other
settings. Although multiple variables undoubtedly contribute
to clinical outcome for patients diagnosed with early-stage
colorectal cancer, these preliminary findings indicate that
cIAP2, Apaf1, TUCAN, and Bcl-2 deserve further evaluation as
potential prognostic markers. If confirmed in prospective
studies, such prognostic biomarkers may help to guide
treatment decisions for colorectal cancer patients, particularly
regarding use of adjuvant chemotherapy.
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